Why Icon PLC (ICLR) is a Top Value Stock for the Long-Term
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike.
While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks based on value, growth, and/or momentum characteristics.
Why Investors Should Pay Attention to This Value Stock
Different than growth or momentum investors, value-focused investors are all about finding good stocks at good prices, and discovering which companies are trading under what their true value is before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, and Price/Cash Flow to help pick out the most attractive and discounted stocks.
Icon PLC (ICLR)
Founded in Dublin, Ireland, in 1990, ICON Public Limited Company (“ICON plc”) is a clinical research organization (CRO). The company is a provider of outsourced development and services to pharmaceutical, biotechnology, medical device and government and public health organizations.
ICLR boasts a Value Style Score of B and VGM Score of B, and holds a Zacks Rank #3 (Hold) rating. Shares of Icon PLC are trading at a forward earnings multiple of 21.3X, as well as a PEG Ratio of 1.4, a Price/Cash Flow ratio of 16.5X, and a Price/Sales ratio of 3.2X.
A company's earnings performance is important for value investors as well. For fiscal 2024, four analysts revised their earnings estimate higher in the last 60 days for ICLR, while the Zacks Consensus Estimate has increased $0.02 to $15.09 per share. ICLR also holds an average earnings surprise of 0.9%.
ICLR should be on investors' short lists because of its impressive earnings and valuation fundamentals, a good Zacks Rank, and strong Value and VGM Style Scores.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ICON PLC (ICLR) : Free Stock Analysis Report